Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

For older adults with type 2 diabetes, GLP-1 RA use is associated with nonarteritic anterior ischemic optic neuropathy.

Innovent Biologics receives US FDA clearance to initiate phase 1 clinical trial of novel oral GLP-1R agonist, IBI3032: San Francisco Wednesday, August 6, 2025, 14:00 Hrs [IST] Inn ...

Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health:In patients with type 2 diabetes (T2D) not achieving glycemic targets, ...

Eris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March ...

An older woman with dementia and type 2 diabetes was started on semaglutide and subsequently developed severe psychological and physical symptoms, including apathy, significant weight loss and ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Learn more about the gut microbiome’s digestion of the amino acid tryptophan, which creates byproducts with potential for ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (NASDAQ: MDGL) announced Monday it has secured exclusive global rights to develop ...

Conshohocken, Pa. Friday, August 1, 2025, 15:00 Hrs [IST] ...

Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in ...

License agreement supports Madrigal's pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra (resmetirom) Combining Rezdiffra with the ...